Pulmonx (LUNG) Net Income towards Common Stockholders (2019 - 2025)

Pulmonx (LUNG) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$13.9 million in Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 1.52% year-over-year to -$13.9 million in Q3 2025; TTM through Dec 2025 was -$43.6 million, a 22.82% increase from a year earlier, with the FY2024 full-year figure at -$56.4 million, up 7.31% from the prior year.
• Net Income towards Common Stockholders for Q3 2025 stood at -$13.9 million, up from -$15.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for LUNG reached as high as -$10.1 million in Q3 2021 and fell as low as -$16.2 million in Q2 2023.
• Historically, Net Income towards Common Stockholders has averaged -$14.1 million across 5 years, with a median of -$14.2 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders plunged 162.62% in 2021 and rose 13.22% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$13.0 million in 2021, then decreased by 9.87% to -$14.3 million in 2022, then grew by 2.81% to -$13.9 million in 2023, then climbed by 5.13% to -$13.2 million in 2024, then retreated by 5.72% to -$13.9 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$13.9 million in Q3 2025, -$15.2 million in Q2 2025, and -$14.4 million in Q1 2025.